


India

ADD (no change)

Consensus ratings*:	Buy 9	Hold 3	Sell 0
Current price:	Rs288		
Target price:	Rs318 ▲		
Previous target:	Rs303		
Up/downside:	10.4%		
InCred Research / Consensus:	-11.9%		
Reuters:			
Bloomberg:	BSOFT IN		
Market cap:	US\$1,089m		
	Rs79,094m		
Average daily turnover:	US\$9.1m		
	Rs662.5m		
Current shares o/s:	279.0m		
Free float:	59.0%		
*Source: Bloomberg			

Key changes in this note

- Expect 6.2% US\$ revenue CAGR over FY23-25F.
- Expect 27.6% EBIT CAGR over FY23-25F.
- Expect 32.9% PAT CAGR over FY23-25F.



Price performance	1M	3M	12M
Absolute (%)	8.2	(0.2)	(25.6)
Relative (%)	4.8	(1.7)	(34.4)

Major shareholders	% held
Axis Small Cap fund	5.5
ICICI Prudential Small Cap Fund	4.4
Aditya Birla Sunlife Digital India	3.0

Analyst(s)

Abhishek SHINDADKAR
T (91) 22 4161 1543
E abhishek.shindadkr@incredcapital.com

Tushar WAVHAL
T (91) 22 4161 1544
E tushar.wavhal@incredcapital.com

Birlasoft

Slow and steady in the right direction

- 4QFY23 revenue growth was better than feared while EBIT margin was in line.
- Management believes new organization structure could drive better synergy, higher efficiency, and deeper customer engagement.
- Retain ADD rating with a higher target price of Rs318 vs. Rs303 earlier.

4QFY23 earnings summary

Birlasoft's (BSOFT) 4QFY23 constant currency (CC) adjusted revenue (ex-Invacare) was above estimate (up 3.1% qoq in CC terms) while the EBITDA margin was in line. Deal wins were encouraging while management commentary suggests organizational restructuring with a sharpened focus on 1) vertical-led go-to-market strategy, 2) four service offerings (Digital & Cloud, Data & Analytics, Enterprise Resource Planning or ERP and Infrastructure), and 3) the cultural transformation is largely complete. Together, this could drive better synergy, higher efficiency, and deeper customer engagement and help in sustainable growth recovery. However, we believe that growth recovery could be taxing this time given the lack of sectoral tailwinds witnessed post Covid-19 pandemic and hence, model a modest 6.2% revenue growth CAGR over FY23-FY25F.

Strong TCV wins for the second consecutive quarter

New deal TCV at US\$114m was up 11.8% qoq but down 8.8% yoy. TCV wins, including renewals, at US\$286m were up by a healthy 23.8% qoq and 28.8% yoy. LTM TCV, including renewals, stood at US\$868m vs. US\$804m in 3QFY23 and US\$697m in 4QFY22. Birlasoft won one US\$50m+ deal with 60% renewal and 40% new component. Although the deal pipeline and win commentary were encouraging, management highlighted that ramp-up delay remains a key monitorable.

Retains medium-term target of 15% EBITDA margin

4QFY23 EBIT margin at 11.9% (in line with our estimate) was up 70bp qoq vs. adjusted EBIT margin of 11.2% in 3QFY23. Investments in leadership, capabilities, services offerings and the go-to-market strategy driven by organization restructuring and wage hike (in 2QFY24F) are key margin headwinds in FY24F while growth leverage, gains from operational efficiency, tail account rationalization and moderation in wage inflation are key tailwinds. We expect an average 12.4% EBIT margin over FY24F-25F.

Retain ADD rating with a higher target price of Rs318

We expect 6.2% US\$ revenue CAGR over FY23-25F and retain ADD rating on Birlasoft with a higher target price of Rs318 (Rs303 earlier) as we incorporate 4QFY23 earnings and despite retaining our target PE/G multiple of ~1x FY25F PAT growth (provision of Rs1.5bn in 3QFY23 distorts FY23-FY25F EPS CAGR). Strong cash generation, net cash of Rs37 per share, healthy payout ratio and relative low valuation provides cushion, in our view. Client-specific issues and weak execution are key downside risks.

Financial Summary	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Revenue (Rsm)	35,557	41,304	47,948	51,692	56,343
Operating EBITDA (Rsm)	5,292	6,401	5,205	7,150	8,057
Net Profit (Rsm)	3,208	4,638	3,316	5,091	5,854
Core EPS (Rs)	11.5	16.4	11.8	18.2	21.0
Core EPS Growth	41.7%	42.5%	(27.8%)	54.4%	15.0%
FD Core P/E (x)	25.04	17.57	24.35	15.77	13.71
DPS (Rs)	3.5	4.5	3.5	5.0	6.0
Dividend Yield	1.22%	1.56%	1.22%	1.74%	2.09%
EV/EBITDA (x)	13.30	11.05	13.64	9.43	7.86
P/FCFE (x)	15.07	57.53	32.37	20.40	15.66
Net Gearing	(45.8%)	(41.7%)	(39.9%)	(45.6%)	(52.4%)
P/BV (x)	3.72	3.17	3.30	2.85	2.48
ROE	15.8%	19.5%	13.2%	19.3%	19.3%
% Change In Core EPS Estimates				0.15%	0.56%
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 1: Quarterly performance

YE Mar (Rs m)	4QFY23	4QFY22	YoY (%)	3QFY23	QoQ (%)	4QFY23F	Var. (%)
Revenue (US\$ m)	149.1	146.4	1.8	148.4	0.5	147.1	1.4
Revenue (Rs m)	12,264	11,014	11.3	12,219	0.4	12,109	1.3
USD-INR realization	82.3	75.2	9.3	82.3	(0.1)	82.3	(0.1)
EBITDA	1,670	1,745	(4.3)	74	2168.8	1,659	0.6
EBITDA Margin (%)	13.6	15.8	(223 bp)	0.6	1301 bp	13.7	(9 bp)
EBIT	1,460	1,546	(5.5)	-136	(1170.7)	1,449	0.8
EBIT Margin (%)	11.9	14.0	(213 bp)	-1.1	1302 bp	12.0	(6 bp)
Depreciation	210	200	5.0	210	(0.2)	210	(0.2)
Net other income	-63	190	(133.0)	68	(192.3)	65	(195.9)
PBT	1,397	1,736	(19.5)	-68	(2145.4)	1,514	(7.7)
Provision for tax	276	407	(32.3)	95	189.1	382	(27.8)
% tax rate	19.7	23.4	(372 bp)	-139.5	15923 bp	25.2	(548 bp)
Net Profit	1,122	1,329	(15.6)	-165	(781.4)	1,133	(1.0)
EPS (Rs)	4.0	4.7	(15.6)	-0.6	(781.4)	4.1	(1.6)

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Key takeaways from earnings call

- US\$ revenue (ex-Invacare) at US\$149.1m (up 0.5% qoq and 1.8% yoy) was up 3.3% qoq and 6.4% yoy. CC revenue (ex-Invacare) was up 3.1% qoq in 4QFY23 and up 11.5% in FY23.
- 4QFY23 execution was driven by strong execution of deals. Management expects the growth momentum to continue but the rate of growth hinges on the on macroeconomic environment, which remains challenged.
- Management expect slow decision-making in the near term as the priority shifts to drive operational and cost improvement programs vs. transformational.
- **Organization restructuring:** The organization has been restructured with vertical go-to-market strategy for better synergies, higher efficiencies, and deeper customer engagement. The North America geography would focus on manufacturing, BFSI, Energy & Utilities verticals with P&L being managed by respective leaders and reporting to the North America CEO. The European and RoW geographies have separate leaders with a mandate to expand footprint. The role of the chief growth officer would be to drive and create marketable solutions, strategic partnership, improve industry as well as advisory outreach and manage marketing functions. In terms of service lines, the focus would be on a) Digital & Cloud, b) Data & Analytics, c) ERP, and d) Infrastructure. Cultural transformation to focus growth mindset, customer centricity, decision-making, and employee centricity with an aim to reorient and optimize for greater accountability and agility. Overall, ~90% restructuring is complete with appointments for critical roles with others to be filled in the coming days.
- Better growth prospects in the BFSI vertical (20.5% of revenue), given no exposure to regional banks. Witnessing good traction in the payments and lending space. Winning share in vendor consolidation.
- Although the Manufacturing vertical (47.1%) could be soft in the near term, select green shoots are visible and could help recovery in a couple of quarters.
- Energy & Utilities vertical's (14.9%) growth is likely to be soft in the near term.
- Optimistic on Lifesciences vertical (17.6%) but on a wait-and-watch mode driven by the consolidation theme.
- Management has decided to consolidate all offerings of ERP business mix (35.8% of revenue) under one leader (Mr. Ravi Purohit – Global ERP Head). Management expects growth to recovery as the business has bottomed out.
- Management is aiming at 15% EBITDA margin in the medium term. Gains from operational efficiency would be offset by investments in strengthening leadership, service offerings and delivery. Wage hike would be a margin headwind in 2QFY24F.
- Client rationalizing exercise (288 active clients; down 13 over previous two quarters) to continue in the medium term.

- Awaiting clarity from auditors on the accounting of Invacare settlement (~US\$2m). Invacare revenue stood at ~US\$14m in 9MFY23. Invacare cost would not be part of P&L, starting 1 Jun 2023F.
- Birlasoft expects an effective tax rate of ~25% in FY24F.
- Employee count was down 2.7% qoq and 0.1% yoy at 12,193. LTM attrition was at 22.1% vs. 25.5% in 3QFY23. Utilization was up 80bp qoq at 84.8%.

Figure 2: Operating metrics trends

Operating trends	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Revenue (US\$ m)	123.3	128.4	136.9	143.4	146.4	148.6	148.8	148.4	149.1
Growth YoY (%)	-1.8	5.9	18.4	20.0	18.7	15.7	8.7	3.5	1.8
Growth QoQ (%)	3.2	4.1	6.6	4.7	2.1	1.5	0.1	-0.3	0.5
Revenue (INR m)	9,028.6	9,453.2	10,116.9	10,719.1	11,014.4	11,544.1	11,920.8	12,218.9	12,263.9
Growth YoY (%)	-0.5	3.4	18.0	21.7	22.0	22.1	17.8	14.0	11.3
Growth QoQ (%)	2.5	4.7	7.0	6.0	2.8	4.8	3.3	2.5	0.4
EBIT Margin (%)	14.9	14.0	13.1	13.4	14.0	13.0	13.1	-1.1	11.9
US\$-INR realized rate	73.2	73.6	73.9	74.7	75.2	77.7	80.1	82.3	82.3
Headcount	11,051	11,508	12,065	11,945	12,204	12,565	12,758	12,530	12,193
Utilization (%)	82.8	85.0	85.8	85.4	85.2	82.5	82.4	84.0	84.8
LTM Attrition (%)	NA	14.9	21.5	27.3	29.4	27.9	27.4	25.5	22.1
Vertical (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
BFSI	18.3	17.5	18.1	17.7	17.2	17.8	19.1	20.1	20.5
Energy & Utilities	14.8	14.9	14.3	14.8	15.1	14.3	14.1	13.9	14.9
Lifesciences	24.6	23.4	24.2	22.3	21.6	21.2	19.6	19.9	17.6
Manufacturing	42.3	44.2	43.4	45.2	46.1	46.7	47.2	46.1	47.1
Vertical (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
BFSI	22.6	22.5	24.8	25.4	25.2	26.5	28.4	29.8	30.6
Energy & Utilities	18.2	19.1	19.6	21.2	22.1	21.2	21.0	20.6	22.2
Lifesciences	30.3	30.0	33.1	32.0	31.6	31.5	29.2	29.5	26.2
Manufacturing	52.2	56.8	59.4	64.8	67.5	69.4	70.2	68.4	70.2
Vertical YoY (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
BFSI	5.1	6.5	14.6	13.6	11.6	17.7	14.7	17.5	21.4
Energy & Utilities	-14.5	1.8	12.2	20.0	21.1	11.1	7.2	-2.8	0.5
Lifesciences	-4.2	-13.9	19.4	9.7	4.3	4.9	-12.0	-7.7	-17.0
Manufacturing	2.3	21.9	21.5	28.8	29.4	22.3	18.2	5.5	4.1
Vertical QoQ (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
BFSI	1.0	-0.4	10.3	2.4	-0.8	5.0	7.4	5.0	2.5
Energy & Utilities	3.2	4.8	2.3	8.4	4.2	-3.9	-1.3	-1.7	7.7
Lifesciences	4.0	-0.9	10.3	-3.5	-1.1	-0.4	-7.4	1.3	-11.1
Manufacturing	3.7	8.8	4.7	9.1	4.1	2.8	1.2	-2.6	2.7
Incremental revenue (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
BFSI	0.2	-0.1	2.3	0.6	-0.2	1.3	2.0	1.4	0.7
Energy & Utilities	0.6	0.9	0.4	1.6	0.9	-0.9	-0.3	-0.4	1.6
Lifesciences	1.2	-0.3	3.1	-1.2	-0.4	-0.1	-2.3	0.4	-3.3
Manufacturing	1.8	4.6	2.7	5.4	2.7	1.9	0.8	-1.8	1.8
Geography (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Americas	79	80.7	82.2	82.9	82.2	84.9	84.1	83.7	85.3
Europe	12.5	11.8	10.5	10.7	11.2	9.2	9.6	10.3	9.0
ROW	8.5	7.5	7.3	6.4	6.6	5.9	6.3	6.0	5.7
Geography (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Americas	97.4	103.6	112.5	118.9	120.3	126.2	125.1	124.2	127.2
Europe	15.4	15.2	14.4	15.3	16.4	13.7	14.3	15.3	13.4
ROW	10.5	9.6	10.0	9.2	9.7	8.8	9.4	8.9	8.5
Geography YoY (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Americas	-5.0	14.6	26.3	27.0	23.5	21.8	11.2	4.5	5.7
Europe	41.0	-16.1	-6.5	-1.2	6.4	-9.8	-0.6	-0.4	-18.2
ROW	-14.0	-24.3	-9.9	-11.7	-7.8	-9.0	-6.2	-3.0	-12.0
Geography QoQ (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Americas	4.1	6.4	8.6	5.6	1.2	4.8	-0.8	-0.7	2.4
Europe	-0.8	-1.7	-5.1	6.7	6.9	-16.6	4.5	7.0	-12.2
ROW	0.8	-8.1	3.8	-8.2	5.3	-9.3	6.9	-5.0	-4.6
Incremental revenue (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Americas	3.8	6.2	8.9	6.3	1.5	5.8	-1.0	-0.9	3.0
Europe	-0.1	-0.3	-0.8	1.0	1.1	-2.7	0.6	1.0	-1.9
ROW	0.1	-0.9	0.4	-0.8	0.5	-0.9	0.6	-0.5	-0.4
Services (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Business technology & transformation	35.5	37.1	36.9	36.7	36.5	38.6	39.9	42.2	42.6
Enterprise solutions	44.7	43.1	41.0	41.6	40.9	40.2	37.7	35.1	35.8
Cloud & Base services	19.8	19.8	22.1	21.7	22.6	21.2	22.5	22.8	21.6
Services (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Business technology & transformation	43.8	47.6	50.5	52.6	53.4	57.4	59.4	62.6	63.5
Enterprise solutions	55.1	55.3	56.1	59.7	59.9	59.7	56.1	52.1	53.4
Cloud & Base services	24.4	25.4	30.3	31.1	33.1	31.5	33.5	33.8	32.2
Services YoY (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Business technology & transformation	NA	22.8	29.3	30.7	22.1	20.4	17.5	19.0	18.9
Enterprise solutions	NA	-5.3	-0.7	8.1	8.6	7.9	-0.1	-12.7	-10.9
Cloud & Base services	NA	5.9	51.3	29.6	35.5	23.9	10.7	8.7	-2.7
Services QoQ (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Business technology & transformation	8.7	8.8	6.0	4.2	1.5	7.3	3.5	5.5	1.4
Enterprise solutions	-0.2	0.4	1.4	6.3	0.4	-0.2	-6.1	-7.1	2.5
Cloud & Base services	1.6	4.1	19.0	2.9	6.3	-4.8	6.3	1.1	-4.8
Incremental revenue (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23

Business technology & transformation	3.5	3.9	2.9	2.1	0.8	3.9	2.0	3.3	0.9
Enterprise solutions	-0.1	0.2	0.8	3.5	0.2	-0.1	-3.6	-4.0	1.3
Cloud & Base services	0.4	1.0	4.8	0.9	2.0	-1.6	2.0	0.4	-1.6
New deal wins (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Order intake	162	94	104	121	125	112	138	102	114
QoQ (%)	189.3	-42.0	10.6	16.3	3.3	-10.4	23.2	-26.1	11.8
YoY (%)	141.8	5.6	-13.3	116.1	-22.8	19.1	32.7	-15.7	-8.8
TTM order intake	427	432	416	481	444	462	496	477	466
Clients (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Top 5	32.8	30.5	29.7	29.3	29.9	30.7	31.1	31.7	32.8
Top 6-10	12.3	13.9	15.5	16.2	15.8	16.3	16.1	16.2	15.9
Top 11-20	15.6	16.0	16.0	15.6	15.6	16.1	16.5	16.2	15.2
Non-top 20	39.3	39.6	38.8	38.9	38.7	36.9	36.3	35.9	36.1
Clients (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Top 5	40.4	39.2	40.7	42.0	43.8	45.6	46.3	47.0	48.9
Top 6-10	15.2	17.8	21.2	23.2	23.1	24.2	24.0	24.0	23.7
Top 11-20	19.2	20.5	21.9	22.4	22.8	23.9	24.6	24.0	22.7
Non-top 20	48.5	50.8	53.1	55.8	56.7	54.8	54.0	53.3	53.8
Clients YoY (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Top 5	14.6	5.6	10.3	6.9	8.2	16.5	13.8	12.0	11.7
Top 6-10	0.6	23.7	50.5	60.7	52.5	35.7	12.9	3.5	2.5
Top 11-20	16.0	27.4	31.6	27.3	18.7	16.5	12.1	7.5	-0.8
Non-top 20	-17.4	-5.1	10.7	15.8	16.9	7.8	1.7	-4.5	-5.0
Clients QoQ (%)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Top 5	2.9	-3.2	3.8	3.3	4.2	4.2	1.4	1.7	4.0
Top 6-10	4.9	17.7	18.9	9.5	-0.4	4.7	-1.1	0.4	-1.4
Top 11-20	9.5	6.8	6.6	2.1	2.1	4.8	2.6	-2.1	-5.7
Non-top 20	0.6	4.9	4.5	5.0	1.6	-3.2	-1.5	-1.4	1.0
Incremental revenue (US\$ m)	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Top 5	1.1	-1.3	1.5	1.4	1.8	1.8	0.7	0.8	1.9
Top 6-10	0.7	2.7	3.4	2.0	-0.1	1.1	-0.3	0.1	-0.3
Top 11-20	1.7	1.3	1.4	0.5	0.5	1.1	0.6	-0.5	-1.4
Non-top 20	0.3	2.4	2.3	2.7	0.9	-1.8	-0.8	-0.7	0.5
Client metrics	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Active clients	291	291	280	285	296	300	301	299	288
Revenue per active client	1.65	1.67	1.81	1.87	1.88	1.92	1.95	1.98	2.07
US\$ 1 m+	76	77	76	77	80	82	76	83	83
US\$ 5 m+	22	22	20	21	25	25	27	24	26
US\$ 10 m+	9	10	12	12	13	13	14	13	13
Per employee analysis	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23
Revenue (US\$ m) - TTM	479.6	486.8	508.1	532.0	555.1	575.3	587.2	592.2	594.9
Employees (average TTM)	10,342	10,742	11,256	11,642	11,931	12,195	12,368	12,514	12,512
Revenue per employee (TTM)	46,374	45,317	45,141	45,696	46,528	47,176	47,477	47,322	47,548


SOURCE: INCRED RESEARCH, COMPANY REPORTS

Figure 3: Change in our earnings estimate

Y/E, Mar (Rs m)	FY24F			FY25F		
	New	Old	% change	New	Old	% change
US\$ revenue	623	621	0.3	671	664	1.0
Revenue	51,692	51,524	0.3	56,343	55,795	1.0
EBIT	6,267	6,497	-3.5	7,139	7,344	-2.8
EBIT Margin (%)	12.1	12.6	(49) bp	12.7	13.2	(49) bp
Net PAT	5,091	5,052	0.8	5,854	5,786	1.2
EPS (Rs)	18.2	18.2	0.8	21.0	20.9	1.2

SOURCE: COMPANY REPORTS, INCRED RESEARCH

BY THE NUMBERS



Profit & Loss

(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Total Net Revenues	35,557	41,304	47,948	51,692	56,343
Gross Profit	14,373	17,614	19,817	20,885	22,931
Operating EBITDA	5,292	6,401	5,205	7,150	8,057
Depreciation And Amortisation	(804)	(765)	(823)	(883)	(918)
Operating EBIT	4,489	5,636	4,382	6,267	7,139
Financial Income/(Expense)	59	532	42	539	667
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)					
Profit Before Tax (pre-EI)	4,548	6,168	4,424	6,806	7,806
Exceptional Items					
Pre-tax Profit	4,548	6,168	4,424	6,806	7,806
Taxation	(1,340)	(1,530)	(1,108)	(1,715)	(1,951)
Exceptional Income - post-tax					
Profit After Tax	3,208	4,638	3,316	5,091	5,854
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	3,208	4,638	3,316	5,091	5,854
Recurring Net Profit	3,208	4,638	3,316	5,091	5,854
Fully Diluted Recurring Net Profit	3,208	4,638	3,316	5,091	5,854

Cash Flow

(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
EBITDA	5,292	6,401	5,205	7,150	8,057
Cash Flow from Invt. & Assoc.					
Change In Working Capital	845	(2,563)	(800)	(889)	(379)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	108				
Other Operating Cashflow					
Net Interest (Paid)/Received					
Tax Paid	(667)	(1,784)	(1,315)	(1,715)	(1,951)
Cashflow From Operations	5,579	2,055	3,090	4,546	5,726
Capex	(249)	(638)	(577)	(600)	(600)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(4,196)	(2,429)	3,094	698	825
Cash Flow From Investing	(4,444)	(3,067)	2,517	98	225
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(554)	(1,111)	(5,994)	(1,395)	(1,674)
Preferred Dividends					
Other Financing Cashflow	(415)	(357)	(368)	(159)	(159)
Cash Flow From Financing	(969)	(1,467)	(6,362)	(1,554)	(1,833)
Total Cash Generated	165	(2,479)	(755)	3,090	4,119
Free Cashflow To Equity	5,330	1,416	2,512	3,946	5,126
Free Cashflow To Firm	1,134	(1,012)	5,607	4,644	5,952

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Total Cash And Equivalents	10,983	11,689	10,425	13,516	17,634
Total Debtors	6,318	8,488	9,071	10,197	10,805
Inventories					
Total Other Current Assets	3,752	4,156	2,201	2,201	2,201
Total Current Assets	21,053	24,333	21,698	25,914	30,641
Fixed Assets	2,466	2,601	2,390	2,107	1,789
Total Investments	353	703	1,014	1,014	1,014
Intangible Assets	4,581	4,673	5,034	5,034	5,034
Total Other Non-Current Assets	1,492	1,524	1,737	1,737	1,737
Total Non-current Assets	8,892	9,500	10,175	9,892	9,574
Short-term Debt					
Current Portion of Long-Term Debt					
Total Creditors	1,318	2,095	2,313	2,549	2,779
Other Current Liabilities	5,026	4,504	3,927	3,927	3,927
Total Current Liabilities	6,343	6,599	6,240	6,477	6,706
Total Long-term Debt					
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	1,802	1,404	1,150	1,150	1,150
Total Non-current Liabilities	1,802	1,404	1,150	1,150	1,150
Total Provisions					
Total Liabilities	8,145	8,003	7,390	7,626	7,855
Shareholders Equity	21,799	25,831	24,483	28,179	32,359
Minority Interests					
Total Equity	21,799	25,831	24,483	28,179	32,359

Key Ratios					
	Mar-21A	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Revenue Growth	8.0%	16.2%	16.1%	7.8%	9.0%
Operating EBITDA Growth	36.8%	21.0%	(18.7%)	37.4%	12.7%
Operating EBITDA Margin	14.9%	15.5%	10.9%	13.8%	14.3%
Net Cash Per Share (Rs)	35.43	37.86	34.79	46.07	60.83
BVPS (Rs)	77.36	90.75	87.25	100.99	115.97
Gross Interest Cover	34.41	43.30	23.57	39.47	44.97
Effective Tax Rate	29.5%	24.8%	25.1%	25.2%	25.0%
Net Dividend Payout Ratio	30.7%	27.6%	29.6%	27.4%	28.6%
Accounts Receivables Days	74.20	65.42	66.83	68.03	68.03
Inventory Days					
Accounts Payables Days	27.75	26.29	28.60	28.80	29.10
ROIC (%)	22.7%	34.6%	22.1%	33.0%	36.2%
ROCE (%)	14.8%	17.1%	12.7%	17.4%	17.3%
Return On Average Assets	11.1%	13.3%	10.0%	13.9%	14.1%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.